The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide

The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide

Enzalutamide is a second-generation androgen receptor inhibitor that increases overall survival (OS) rates in patients with metastatic castration-resistant prostate cancer (mCRPC). This study evaluates the efficacy of circulating tumor cell (CTC) status as a prognostic biomarker following enzalutami...

Full description

Bibliographic Details
Main Authors:	So Nakamura, Masayoshi Nagata, Naoya Nagaya, Takeshi Ashizawa, Hisashi Hirano, Yan Lu, Hisamitsu Ide, Shigeo Horie
Format:	Article
Language:	English
Published:	MDPI AG 2024-02-01
Series:	Cancers
Subjects:	circulating tumor cells (CTCs) enzalutamide bone metastases castration-resistant prostate cancer androgen receptor signaling inhibitor
Online Access:	https://www.mdpi.com/2072-6694/16/4/772

Similar Items

Modern antiandrogenic therapy of patients with castration-resistant prostate cancer without metastases
by: S. V. Popov
Published: (2020-12-01)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
by: Chi-Shin Tseng, et al.
Published: (2023-06-01)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
by: Xiangyun You, et al.
Published: (2023-04-01)

Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer
by: Takuya Tsujino, et al.
Published: (2023-10-01)

Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa
by: Koji Mita, et al.
Published: (2024-01-01)

Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer
by: Marcus Moses, MS, et al.
Published: (2020-01-01)

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer
by: Pier Vitale Nuzzo, et al.
Published: (2023-02-01)

Transcription factor 4 expression in circulating tumor cells from castration‐resistant prostate cancer
by: Naoya Nagaya, et al.
Published: (2021-05-01)

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
by: Kouji Izumi, et al.
Published: (2022-07-01)

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
by: Taro Iguchi, et al.
Published: (2019-04-01)

Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
by: Luo J, et al.
Published: (2016-11-01)

Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran
by: Zahra Goudarzi, et al.
Published: (2024-02-01)

Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
by: Mikio Sugimoto, et al.
Published: (2022-09-01)

Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial
by: Kouji Izumi, et al.
Published: (2017-10-01)

Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
by: Xu Wen, et al.
Published: (2023-05-01)

Possibilities of treatment of patients with castrationrefractory prostate cancer using enzalutamide
by: B. Ya. Alekseyev, et al.
Published: (2019-12-01)

Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer
by: Taizo Uchimoto, et al.
Published: (2021-01-01)

TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model
by: Louie Semaan, et al.
Published: (2019-10-01)

Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients
by: Ali Alkan, et al.
Published: (2021-09-01)

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
by: Meng Wu, et al.
Published: (2023-01-01)

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
by: Nair Lopes, et al.
Published: (2021-08-01)

Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study
by: Huanyi Lin, et al.
Published: (2021-04-01)

Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer
by: Hung-Ming Lam, et al.
Published: (2018-05-01)

THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01)

Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report
by: Tomas Pokrivcak, et al.
Published: (2024-04-01)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
by: Hiroji Uemura, et al.
Published: (2022-01-01)

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
by: Zeyuan Zheng, et al.
Published: (2022-10-01)

Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide
by: Zhe Hong, et al.
Published: (2021-07-01)

Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authors’ experience
by: T. V. Ustinova, et al.
Published: (2021-12-01)

Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy
by: Wenjun Jiang, et al.
Published: (2020-03-01)

Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide
by: Masaki Hirabatake, et al.
Published: (2022-05-01)

Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone—A Retrospective Study
by: Hao Xiang Chen, et al.
Published: (2023-07-01)

Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use
by: Cheng-Kuang Yang, et al.
Published: (2023-04-01)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
by: Shigetomo Yamada, et al.
Published: (2022-03-01)

Abiraterone Rechallenge Based on Sequential Testing of Androgen Receptor Splice Variant 7 Expression in Circulating Tumor Cells: A Case Report
by: Naoya Nagaya, et al.
Published: (2020-04-01)

A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer
by: Yan Li, et al.
Published: (2022-11-01)

Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review
by: Wei Zhang, et al.
Published: (2017-01-01)

Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway
by: Yong Luo, et al.
Published: (2021-10-01)

Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate
by: Ondřej Fiala, et al.
Published: (2024-01-01)

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
by: Anders Bjartell, et al.
Published: (2022-11-01)